MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 03 2023
Historique:
received: 17 09 2022
accepted: 20 03 2023
entrez: 24 3 2023
pubmed: 25 3 2023
medline: 28 3 2023
Statut: epublish

Résumé

We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with photons. We retrospectively analyzed a total of 154 pre- and post-irradiation MRI datasets of 36 patients with low-grade, Ann-Arbor stage I, orbital non-Hodgkin lymphomas. Patients with restricted conjunctival involvement were excluded. Lymphoma lesions were delineated and volumetrically analyzed on T1-weighted sequences. Tumor residues were present in 91.2% of all cases during the first six months after treatment. Volumetric partial response rates (> 50% volume reduction) were 75%, 69.2%, and 50% at 12-24 months, 36-48 months and > 48 months after the end of treatment. The corresponding complete response (CR) rates according to the Lugano classification were 20%, 23.1% and 50%. During a median clinical follow-up of 37 months no significant differences in progression free survival (PFS) rates were observed between the CR and non-CR group (p = 0.915). A residual tumor volume below 20% of the pretreatment volume should be expected at long-term follow-up beyond one year after radiotherapy.

Identifiants

pubmed: 36959374
doi: 10.1038/s41598-023-31941-w
pii: 10.1038/s41598-023-31941-w
pmc: PMC10036339
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4792

Informations de copyright

© 2023. The Author(s).

Références

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):650-4
pubmed: 24521680
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1387-93
pubmed: 20950950
Eur Radiol. 2021 Dec;31(12):8925-8936
pubmed: 34021390
Asia Pac J Clin Oncol. 2019 Dec;15(6):358-363
pubmed: 31264373
Radiother Oncol. 2009 Feb;90(2):236-41
pubmed: 18950885
Hematol Oncol. 2022 Dec;40(5):922-929
pubmed: 35857866
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):228-33
pubmed: 16503386
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31
pubmed: 25863750
EJNMMI Res. 2019 Nov 21;9(1):99
pubmed: 31754896
Eur Radiol. 2019 Jan;29(1):202-212
pubmed: 29948084
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ocul Oncol Pathol. 2017 Sep;3(3):181-187
pubmed: 29134184
Ann Hematol. 2015 Jul;94(7):1185-93
pubmed: 25728714
Lancet Oncol. 2014 Apr;15(4):457-63
pubmed: 24572077
Cancer. 2003 Aug 15;98(4):865-71
pubmed: 12910532
Br J Radiol. 2022 Feb 01;95(1130):20210635
pubmed: 34919440
EClinicalMedicine. 2018 Oct 17;4-5:32-42
pubmed: 31193655
Int J Oncol. 2020 Feb;56(2):417-429
pubmed: 31939615
Anticancer Res. 2020 Jul;40(7):4041-4046
pubmed: 32620650
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):86-91
pubmed: 19632068
Clin Nucl Med. 2016 Nov;41(11):837-843
pubmed: 27648705
JAMA Ophthalmol. 2014 Jul;132(7):851-8
pubmed: 24763920
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91
pubmed: 14630277
Eur J Ophthalmol. 2022 Sep;32(5):3092-3096
pubmed: 34318737
Leuk Lymphoma. 2015 May;56(5):1266-70
pubmed: 25356924
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e659-66
pubmed: 21640514
Radiology. 2010 Aug;256(2):565-74
pubmed: 20656841
Radiother Oncol. 2001 May;59(2):139-44
pubmed: 11325441
Anticancer Res. 2013 Dec;33(12):5575-8
pubmed: 24324100
J Magn Reson Imaging. 2015 Dec;42(6):1646-55
pubmed: 25952024
Br J Haematol. 2011 Jan;152(1):72-80
pubmed: 21083656
Clin Cancer Res. 2015 Jun 1;21(11):2506-13
pubmed: 25733598
Blood. 2017 Jan 19;129(3):324-332
pubmed: 27789481
Radiother Oncol. 2011 Jul;100(1):86-92
pubmed: 21664710
Blood. 2022 Jan 13;139(2):240-244
pubmed: 34525196
Am J Ophthalmol. 2019 Mar;199:44-57
pubmed: 30419193
Cancer. 1987 Aug 1;60(3):407-13
pubmed: 3594379

Auteurs

Christian Hoffmann (C)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany. christian.hoffmann2@uk-essen.de.

Christopher Mohr (C)

Department of Oral and Maxillofacial Surgery, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen, Germany.

Patricia Johansson (P)

Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.

Anja Eckstein (A)

Department of Ophthalmology, University Hospital of Essen, Essen, Germany.

Andreas Huettmann (A)

Department of Hematology, University Hospital Essen, Essen, Germany.

Julia von Tresckow (J)

Department of Hematology, University Hospital Essen, Essen, Germany.

Sophia Göricke (S)

Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Cornelius Deuschl (C)

Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Christoph Poettgen (C)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Thomas Gauler (T)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Nika Guberina (N)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Sourour Moliavi (S)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Nikolaos Bechrakis (N)

Department of Ophthalmology, University Hospital of Essen, Essen, Germany.

Martin Stuschke (M)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Maja Guberina (M)

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH